Overview

Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients

Status:
Enrolling by invitation
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The overall objective of this trial is to provide aftercare treatment with Lamazym and to evaluate the safety of repeated Lamzede i.v. treatment of subjects with alpha-Mannosidosis.
Phase:
Phase 3
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Zymenex A/S